Refractory MSS mCRC enrollment comparison to a dif
Post# of 150118
(Total Views: 584)
Posted On: 02/11/2025 12:00:48 PM
Refractory MSS mCRC enrollment comparison to a different trial:
".....which showed that patients with refractory MSS mCRC who did not have active liver metastases (n = 77) achieved an ORR of 23%.."
" Patients with MSI-H or dMMR disease were excluded. Other key exclusion criteria included prior treatment with anti–PD-1, –PD-L1, or –CTLA-4 agents; prior treatment with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf); partial or complete bowel obstruction within 3 months of enrollment, symptoms of obstruction or radiological evidence of impending obstruction; refractory ascites; and liver metastases."
https://www.onclive.com/view/phase-3-dose-det...-r-mss-crc
The liver Exclusions of course, really stand out due to our extremely significant liver news.
Maybe it's also why our trials were sequenced MASH results before CRC enrollment. (????) : )
Non-medical minds like me, would never guess the MASH liver results help expand our Colorectal Cancer enrollment pool, if needed.
We need 60 enrolled.
"Jan. 1st" @ 5 per week.
60 enrolled by April 1st.
May 1st is Interim look
4 weeks to analyze data. (?)
June 1st results.
Given who our CRO is, few disease Exclusions & the massive CRC patient pool, 5 per week might be conservative.
Followed by an unexpected enrollment completion update.
".....which showed that patients with refractory MSS mCRC who did not have active liver metastases (n = 77) achieved an ORR of 23%.."
" Patients with MSI-H or dMMR disease were excluded. Other key exclusion criteria included prior treatment with anti–PD-1, –PD-L1, or –CTLA-4 agents; prior treatment with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf); partial or complete bowel obstruction within 3 months of enrollment, symptoms of obstruction or radiological evidence of impending obstruction; refractory ascites; and liver metastases."
https://www.onclive.com/view/phase-3-dose-det...-r-mss-crc
The liver Exclusions of course, really stand out due to our extremely significant liver news.
Maybe it's also why our trials were sequenced MASH results before CRC enrollment. (????) : )
Non-medical minds like me, would never guess the MASH liver results help expand our Colorectal Cancer enrollment pool, if needed.
We need 60 enrolled.
"Jan. 1st" @ 5 per week.
60 enrolled by April 1st.
May 1st is Interim look
4 weeks to analyze data. (?)
June 1st results.
Given who our CRO is, few disease Exclusions & the massive CRC patient pool, 5 per week might be conservative.
Followed by an unexpected enrollment completion update.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼